financetom
Business
financetom
/
Business
/
Shopify's Overall Fundamentals Intact Despite Q1 Falling Short of Investor Expectations, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Shopify's Overall Fundamentals Intact Despite Q1 Falling Short of Investor Expectations, Oppenheimer Says
May 9, 2024 10:12 AM

12:33 PM EDT, 05/09/2024 (MT Newswires) -- Shopify's ( SHOP ) Q1 results exceeded management's guidance but fell short of elevated investor expectations, Oppenheimer said in a note Wednesday.

Analysts, including Ken Wong, said that while the results fell short of high buy-side expectations, overall fundamentals seem to be intact. In the future, investors might see that management is giving clearer guidance and expect that the gains from investments in 2024 will continue into 2025, the analysts added.

"Investors anticipating higher profitability on 'sandbagged' operating expenses are now coming to terms with a narrower delta. Cautious investors likely ratchet down 'upside' scenarios, and push out revenue and margin upside to 2025," the analysts said.

Management guided Q2 revenue in line with expectations, despite facing challenges from foreign exchange rates and Europe, Middle East, and Africa headwinds. They expect operating expenses to increase sequentially in Q2 due to spending on Summit and sales and marketing efforts, the analysts said.

The company also expects minimal benefit in Q2 from Shopify Plus pricing with the majority of early renewals opting for three-year contracts, the analysts added.

The analysts said that the ecommerce giant is "well led by a visionary and respected management team" and continues to have "multi-year growth potential."

Oppenheimer has an outperform rating and a $90 price target on the stock.

Price: 62.29, Change: -0.44, Percent Change: -0.71

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: TC Energy to Compensate Investors of Aspen Bond Deal
Market Chatter: TC Energy to Compensate Investors of Aspen Bond Deal
Sep 13, 2024
11:45 AM EDT, 09/13/2024 (MT Newswires) -- TC Energy ( TRP ) will compensate investors of CA$1 billion ($736.1 million) Aspen Investments bond transaction after the deal fell through, Bloomberg News reported Friday, citing the company. Aspen Investments planned to sell the bond and use proceeds to purchase a stake in TC Energy's ( TRP ) network of natural gas...
Update: Exro Technologies Closes $25-Million Share-Unit Offering
Update: Exro Technologies Closes $25-Million Share-Unit Offering
Sep 13, 2024
12:14 PM EDT, 09/13/2024 (MT Newswires) -- Exro Technologies ( EXROF ) said Friday it raised $25 million after closing a share-unit offering priced at $0.35 apiece. The company will use the proceeds to boost growth in deliveries of its propulsion system technologies to commercial vehicle original equipment manufacturers, as well as coil driver innovation programs with major players in...
Chinese courier delivery firm BingEx files for US IPO
Chinese courier delivery firm BingEx files for US IPO
Sep 13, 2024
Sept 13 (Reuters) - Chinese courier delivery firm BingEx, which brands its services as 'FlashEx', has filed to go public in the United States, a regulatory filing showed on Friday. WHY IT'S IMPORTANT Several high-profile companies are trying to test investor appetite for IPOs following a prolonged downturn due to rising interest rates and geopolitical turmoil. The number of Chinese...
Dr. Reddy's Agrees to Partial Deferral of Cancer Therapy-Related Milestone Payment by Citius Oncology
Dr. Reddy's Agrees to Partial Deferral of Cancer Therapy-Related Milestone Payment by Citius Oncology
Sep 13, 2024
12:14 PM EDT, 09/13/2024 (MT Newswires) -- Citius Oncology ( CTOR ) said Friday that Dr. Reddy's Laboratories (RDY) agreed to a partial deferral without penalty of a milestone payment by Citius that was triggered upon the US Food and Drug Administration's approval of the Lymphir cancer therapy. The milestone payment was due Sept. 9, Citius said in a filing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved